

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

Technology Appraisal guidance no.23; Temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Hospira (temozolomide)</li> <li>• Medac (temozolomide)</li> <li>• Merck Sharp and Dohme (temozolomide)</li> <li>• Mylan (temozolomide)</li> <li>• Ratiopharm (temozolomide)</li> <li>• Sandoz (temozolomide)</li> <li>• Teva (temozolomide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Brainstrust</li> <li>• Brain and Spine Foundation</li> <li>• Brain Tumour UK</li> <li>• British Brain Tumour Association</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer 52</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Trust</li> <li>• Macmillan Cancer Support</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Neurological Alliance</li> <li>• Neurosupport</li> <li>• Rarer Cancers Foundation</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Alliance Pharmaceuticals (procarbazine)</li> <li>• Archimedes Pharmaceuticals (carmustine implants)</li> <li>• Bristol-Myers Squibb Pharmaceuticals (carmustine)</li> <li>• Genus Pharmaceuticals (vincristine sulphate)</li> <li>• Hospira UK (vincristine)</li> <li>• Medac UK (lomustine)</li> <li>• Teva UK (vincristine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Brain Tumour Research</li> </ul>

National Institute for Health and Clinical Excellence  
 Technology Appraisal guidance no.23; Temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Date: March 2011

## APPENDIX A

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Samantha Dickson Brain Tumour Trust</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Neuropathological Society</li> <li>• British Oncological Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Institute of Neurology</li> <li>• Primary Care Neurology Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society of British Neurological Surgeons</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Wiltshire</li> <li>• NHS Wirral</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• British Neurological Research Trust</li> <li>• Department of Neurological Science, University of Liverpool</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment</li> </ul> <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

National Institute for Health and Clinical Excellence  
 Technology Appraisal guidance no.23; Temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Date: March 2011

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the *British National Formulary*, and the British Medical Association).

#### Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).